Mayne Pharma Group Ltd (ASX: MYX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mayne Pharma Group Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$239.12 million
P/E Ratio
7.25
Dividend Yield
0.00%
Shares Outstanding
81.89 million
Earnings per share
0.390
Dividend per share
0.04
Year To Date Return
-9.00%
Earnings Yield
13.79%
Franking
100%
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mayne Pharma Group Ltd (ASX: MYX)
Latest News
ASX Share Market News
Returning capital: These ASX companies have been buying back their shares in 2023
Broker Notes
'Attractive valuation': 2 ASX shares QVE analysts just bought
Share Fallers
Why Appen, Bank of Queensland, Kogan, and Mayne Pharma shares are dropping
Share Gainers
Why Arafura, Core Lithium, Mayne Pharma, and Newcrest shares are storming higher
ASX Share Market News
Multiple directors are buying this beaten-up ASX 300 healthcare stock
ASX Share Market News
4 ASX 300 directors buying up their company shares in the past week
Share Gainers
Why Allkem, Argosy Minerals, Mayne Pharma, and NextDC shares are racing higher
Earnings Results
Guess which ASX 300 share has rocketed 27% in 2 days since reporting
Share Gainers
Why De Grey, Kogan, Mayne Pharma, and Mesoblast shares are charging higher
Share Fallers
Why Gold Road, MA Financial, Mayne Pharma, and Westgold shares are dropping today
ASX Share Market News
Why Arafura, Mayne Pharma, Pilbara Minerals, and Tyro shares are dropping today
Share Fallers
Why Coronado, IDP, Mayne Pharma, and Rio Tinto shares are dropping today
Frequently Asked Questions
-
Mayne Pharma made a fully franked cash payment to shareholders in January 2023. Prior to that, the company’s last dividend payout was in 2011.
-
Mayne Pharma Group Ltd listed on the ASX on 29 June 2007.
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 18 Jan 2023 | $0.0272 | 100.00% | Special Cash | 27 Jan 2023 |
MYX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mayne Pharma Group Ltd
Mayne Pharma Group Ltd (ASX: MYX) is a specialty pharmaceutical company focused on commercialising branded and generic pharmaceutical products. Its South Australian manufacturing base produces a portfolio of oral and topical products including tablets, powders, capsules, liquids, and creams.
Mayne Pharma performs limited research and development, typically acquiring off-patent or tail-end pharmaceutical brands. The company also has a contract manufacturing segment and advertises its services in assisting other drug developers in getting their products to market. The Group earns more than 90% of its revenue from the US market.
MYX Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 30 Sep 2026 | $2.92 | $0.09 | 3.18% | 172,975 | $2.81 | $2.92 | $2.81 |
| 29 Sep 2026 | $2.83 | $0.00 | 0.00% | 91,008 | $2.84 | $2.86 | $2.81 |
| 28 Sep 2026 | $2.83 | $0.02 | 0.71% | 104,609 | $2.80 | $2.84 | $2.78 |
| 25 Sep 2026 | $2.81 | $-0.14 | -4.75% | 96,340 | $2.95 | $2.95 | $2.80 |
| 24 Sep 2026 | $2.95 | $0.05 | 1.72% | 237,400 | $2.81 | $2.95 | $2.79 |
| 23 Sep 2026 | $2.90 | $0.03 | 1.05% | 112,162 | $2.88 | $2.90 | $2.83 |
| 22 Sep 2026 | $2.87 | $0.02 | 0.70% | 111,783 | $2.84 | $2.91 | $2.84 |
| 21 Sep 2026 | $2.85 | $-0.16 | -5.32% | 291,645 | $3.00 | $3.00 | $2.84 |
| 18 Sep 2026 | $3.01 | $-0.01 | -0.33% | 272,099 | $3.01 | $3.02 | $2.96 |
| 17 Sep 2026 | $3.02 | $0.02 | 0.67% | 84,767 | $3.00 | $3.03 | $2.97 |
| 16 Sep 2026 | $3.00 | $-0.03 | -0.99% | 83,795 | $3.05 | $3.05 | $3.00 |
| 15 Sep 2026 | $3.03 | $-0.03 | -0.98% | 365,383 | $3.00 | $3.06 | $2.96 |
| 14 Sep 2026 | $3.06 | $0.10 | 3.38% | 77,874 | $2.96 | $3.06 | $2.96 |
| 11 Sep 2026 | $2.96 | $-0.04 | -1.33% | 238,134 | $3.00 | $3.01 | $2.92 |
| 10 Sep 2026 | $3.00 | $-0.18 | -5.66% | 450,658 | $3.15 | $3.17 | $2.99 |
| 09 Sep 2026 | $3.18 | $0.02 | 0.63% | 552,928 | $3.19 | $3.23 | $3.15 |
| 08 Sep 2026 | $3.16 | $0.04 | 1.28% | 508,133 | $3.11 | $3.19 | $3.09 |
| 07 Sep 2026 | $3.12 | $0.01 | 0.32% | 222,285 | $3.15 | $3.15 | $3.09 |
| 04 Sep 2026 | $3.11 | $0.00 | 0.00% | 350,972 | $3.11 | $3.13 | $3.07 |
| 03 Sep 2026 | $3.11 | $-0.01 | -0.32% | 47,033 | $3.20 | $3.20 | $3.10 |
| 02 Sep 2026 | $3.12 | $-0.11 | -3.41% | 269,888 | $3.22 | $3.33 | $3.12 |
| 01 Sep 2026 | $3.23 | $0.13 | 4.19% | 144,051 | $3.10 | $3.24 | $3.10 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 18 Dec 2025 | Shawn O'Brien | Buy | 326,452 | $989,149 |
Conversion of securities.
|
| 18 Dec 2025 | Shawn O'Brien | Expiry | 72,821 | $220,647 |
As advised by the company. lapsed, 568193 Rights
|
| 18 Dec 2025 | Shawn O'Brien | Sell | 129,736 | $401,341 |
On-market trade.
|
| 18 Dec 2025 | Shawn O'Brien | Exercise | 326,452 | $989,149 |
Conversion of securities. 641014 rights
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Professor Bruce Gregory Robinson AC | Non-Executive DirectorNon-Executive Chairman | Aug 2014 |
Prof Robinson has been the head of the Cancer Genetics Unit at the Kolling Institute of Medical Research, Royal North Shore Hospital since 1989. Since 2001, he has been Chairman of Hoc Mai Foundation, a major program in medical and health education and exchange with Vietnam. He is the member of the risk committee.
|
| Ms Ann Custin | Non-Executive Director | Mar 2022 |
Ms Custin, a US resident, has almost 40 years of experience in the healthcare sector. Most recently, Ms Custin was Board Director and CFO of Siemens Medical Solutions (now Siemens Healthineers), a medical technology company with EUR20b in revenues. Previously, she was Chief Operating and Financial Officer of Scient'x Group and President and CEO of USA Draeger Medical Systems. She is the chairperson of the risk committee and chairperson of the people committee.
|
| Mr David Petrie | Non-Executive Director | Sep 2022 |
Mr Petrie is an M&A executive with over 30 years of advisory experience in public and private mergers and acquisitions, capital management and debt and equity raisings. Previously, he spent 23 years at Merrill Lynch/Bank of America including Managing Director and Head of Investment Banking Melbourne. He is the member of the risk committee and People Committee.
|
| Ms Meghan Rivera | Non-Executive Director | Jun 2026 |
Ms Rivera, a US resident, has brought more than 25 years of experience in the US pharmaceutical industry across multiple therapeutic areas including women's health. Ms Rivera's experience includes building, developing and transforming businesses across biopharma, and she has played a role in launching branded products in the US. She is the member of the People Committee.
|
| Mr Jacob Haft Ma-Weaver | Non-Executive Director | Aug 2026 |
Mr Ma-Weaver is the Managing Member of Cable Car Capital, LP (Cable Car), an investment adviser he founded in 2013. Mr Ma-Weaver served on the Board of ARCA biopharma, Inc. from 2022 until its business combination with Oruka Therapeutics in 2024. Mr Ma-Weaver worked as an equity research associate at Dodge & Cox and a corporate finance business analyst at McKinsey & Company.
|
| Ms Laura Loftus | Company Secretary | Mar 2020 |
-
|
| Laura Loftus | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Citicorp Nominees Pty Limited | 8,310,352 | 10.23% |
| BNP Paribas Nominees Pty Ltd <Ib Au Nomis Retailclient> | 7,932,142 | 9.76% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 5,409,304 | 6.66% |
| BMG B J Myx Pty Ltd <Bmgbj Myx Discretionary A/C> | 5,183,477 | 6.38% |
| HSBC Custody Nominees (Australia) Limited <Gsco Customers A/C> | 4,457,159 | 5.49% |
| BNP Paribas Nominees Pty Ltd <Cowen And Co Llc> | 2,406,601 | 2.96% |
| HSBC Custody Nominees (Australia) Limited | 2,298,086 | 2.83% |
| Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> | 2,014,093 | 2.48% |
| BNP Paribas Noms Pty Ltd | 1,496,245 | 1.84% |
| Dr Kenney Wan | 1,355,391 | 1.67% |
| J P Morgan Nominees Australia Pty Limited | 1,275,296 | 1.57% |
| Boardroom Financial Services Pty Limited <Vsa Unrestricted A/C> | 1,240,877 | 1.53% |
| Birbal Investments Pty Ltd | 950,000 | 1.17% |
| IVL Group Pty Ltd | 800,000 | 0.98% |
| Triple Eight Gold Pty Ltd <The Blue Sky A/C> | 760,856 | 0.94% |
| Narlack Pty Ltd <Pipergolou Pension A/C> | 720,000 | 0.89% |
| Rmk Super Pty Ltd <Rmk Personal S/F A/C> | 713,788 | 0.88% |
| Mr Kon Tzimokas | 643,000 | 0.79% |
| Retzos Executive Pty Ltd <Retzos Executive S/Fund A/C> | 596,049 | 0.73% |
| Morgan Stanley Australia Securities (Nominee) Pty Limited <No 1 Account> | 547,397 | 0.67% |
